TOP > 外国特許検索 > COMPOSITION FOR VASCULAR REGENERATION THERAPY, CONTAINING DEDIFFERENTIATED FAT CELLS AS ACTIVE INGREDIENT

COMPOSITION FOR VASCULAR REGENERATION THERAPY, CONTAINING DEDIFFERENTIATED FAT CELLS AS ACTIVE INGREDIENT 新技術説明会

外国特許コード F170008941
整理番号 (S2015-0856-N0)
掲載日 2017年1月20日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP059386
国際公開番号 WO 2016158670
国際出願日 平成28年3月24日(2016.3.24)
国際公開日 平成28年10月6日(2016.10.6)
優先権データ
  • 特願2015-065598 (2015.3.27) JP
発明の名称 (英語) COMPOSITION FOR VASCULAR REGENERATION THERAPY, CONTAINING DEDIFFERENTIATED FAT CELLS AS ACTIVE INGREDIENT 新技術説明会
発明の概要(英語) The present invention addresses the problem of providing a cell for use in a vascular regeneration therapy, which has a superior blood flow-improving effect compared with a bone marrow-derived MSC, an ASC or the like that is a conventional cell for use in a therapy, and which can be obtained easily in an amount sufficient enough for transplantation, and which has stable quality. It is found that a human DFAT has a high neovascularization ability, can exhibit a high proliferation ability after being subcultured and therefore can be produced easily in an amount needed for transplantation, and does not undergo transformation. Therefore, it is found for the first time that a human DFAT is effective for a vascular regeneration therapy for a human body. These findings lead to the accomplishment of the present invention. That is, the present invention provides a blood flow-improving agent containing human dedifferentiated fat cells (human DFAT) as an active ingredient.
従来技術、競合技術の概要(英語) BACKGROUND ART
Conventional, drug therapy and surgical therapy refractory not adapted peripheral arterial disease (hereinafter, simply referred to as PAD) to, autologous bone marrow mononuclear cells were (i) in the ischemic angiogenesis therapy is performed by administering, its effectiveness has been confirmed (TACT study). Then, G-CSF mobilization (ii) peripheral blood mononuclear cells, adipose tissue-derived stromal vascular fraction (SVF) (iii) cells, peripheral blood mononuclear cells (iv), (v) CD34 positive cells G-CSF mobilization, bone marrow-derived CD133 positive cells (vi), (vii) cultured bone marrow mesenchymal stem cells (MSC) (viii) culturing adipose tissue-derived stem cells (ASC) in the same manner as in many forms such as angiogenic therapy using autologous cells has been performed. (I) - (viii) of the above, (vi) - (i) does not perform cell culture, the necessary number of cells in order to obtain large amounts of tissue be needed for high invasiveness and given to the patient. For this reason the collection with a relatively low-invasive (iv) normal 1 except that the number of treatment only once. In addition, (iv) - (i) cells, because the miscellaneous cell population, and safety of the implantation effects is not constant. In addition, (v), (vi) cells, the stem cell marker using the antibodies selected in uniformity of cells by performing an operation can be improved, the complexity associated with preparing the antibody screening efficiency, and thus increases the cost for preparing the problem. (Vii) 10 ml of the cells are harvested and the number of bone marrow fluid, and then used adhesion culture and propagate, (viii) cells, adipose tissue in an enzyme treatment, in the same manner as (vii) to use the adhesion culture and propagate. Therefore, (vii), (viii) cells together, a large amount from a relatively small amount of tissue that can be prepared that has an advantage of being, the method includes traces in adult tissue stem cell is cultured, grown in the method of the invention, it is unavoidable that the cells are mixed into the other, in order to obtain the necessary number of cells in the treatment of culture needs to be repeated several times. The number of treatment is usually performed only once in the 1. The performance of a cell such as the ability to propagate and other individual differences, age, easily influenced by the underlying disease a demerit that. (i) - (Viii) is the problem that common cells, in proportion to the treatment cost, performance and other individual differences, the number of cells required is not obtained (non-responder) and a treatment not cases the presence, in consideration of invasion of the patient and the normal 1 remain in a single treatment, in. At the present time, with the cells of these peripheral arterial disease (PAD) refractory many clinical studies have been made, placebo, control test cells does not yet have a significant effect. Also, in addition to this, rat adipose tissue-derived progenitor cells or a rat adipose tissue-derived mesenchymal stem cells of blood vessels disclosed to be effective (Patent Document 1, 2). The inventors of the present invention, of a non-human animal such as a mouse mature adipocytes derived from adipose tissue to induce de-differentiation of preadipocytes as de-differentiated adipocytes (DFAT) for the first time to establish (Patent Document 3) can be successful, it is possible to induce the differentiation of DFAT, osteoblasts, myoblasts, chondrocytes, can acquire the functions of nerve cells has been shown (patent document 4). In addition, the inventors of the present invention, mouse and rat DFAT angiogenesis can be used together has been clearly positioned in the (non-patent document 1-3). However, a mouse or a rat DFAT attached and of low capacity to proliferate after implantation and increased up to the necessary number of the difficult, transformed by subculture Bench (immortalized) resulting in a higher possibility of the tumor may be implanted safely. For these reasons, in a mouse or a rat human DFAT DFAT of the same phenomenon occurs, is not suitable for the treatment and it has been considered.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NIHON UNIVERSITY
  • 発明者(英語)
  • MATSUMOTO TARO
  • KANO KOICHIRO
  • KAZAMA TOMOHIKO
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
日本大学産官学連携知財センター(通称NUBIC,ニュービック)は,技術移転機関と知的財産本部の機能を兼ね備えた日本大学の産学連携の窓口です。
NUBICは,日本大学全教職員や大学院生・学部学生の豊富なアイデアや研究成果を,知的財産として戦略的に創出・保護・管理し,産業界のニーズとのマッチングを図り,企業の研究開発,新製品開発,新規事業の立上げが円滑に行われるようサポートいたします。
お気軽にご相談ください。

PAGE TOP

close
close
close
close
close
close